These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35598125)

  • 1. Evaluation of Teneligliptin a DPP4 Inhibitor in Terms of Efficacy and Safety with Respect to QT/QTc Prolongation in Patients with Type II Diabetes Mellitus (T2DM).
    Bhosle D; Chandekar B; Alimuddin S
    J Assoc Physicians India; 2022 May; 70(5):11-12. PubMed ID: 35598125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QT/QTc" study (Q-SET study).
    Erande S; Sarwardekar S; Desai B
    Diabetes Metab Syndr Obes; 2019; 12():961-967. PubMed ID: 31417296
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
    Mohan V; Ramu M; Poongothai S; Kasthuri S
    J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
    Wada N; Mori K; Nakagawa C; Sawa J; Kumeda Y; Shoji T; Emoto M; Inaba M
    J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
    Otsuki H; Kosaka T; Nakamura K; Shimomura F; Kuwahara Y; Tsukamoto T
    Int Urol Nephrol; 2014 Feb; 46(2):427-32. PubMed ID: 24014134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
    Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
    Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
    [No Abstract]   [Full Text] [Related]  

  • 13. QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2).
    Saboo B; Ghosh S; Tiwaskar M; Chawla R
    Diabetes Metab Syndr; 2021; 15(5):102264. PubMed ID: 34488059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
    Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
    Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
    Kitada M; Ogura Y; Nitta K; Fujii M; Kanasaki K; Konishi K; Iida Y; Nakagawa A; Koya D
    J Diabetes Investig; 2019 May; 10(3):706-713. PubMed ID: 30136384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
    Kutoh E; Wada A; Terayama S
    Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.